AbbVie
Tracked across 6 events · 47 articles · First seen Feb 01, 2026 · Last active Apr 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
AbbVie is investing $380 million to construct two new active pharmaceutical ingredient manufacturing facilities, which will strengthen its U.S. manufacturing capabilities and support the production of next-generation neuroscience and obesity medications. This investment is part of a larger $100 billion commitment to U.S. R&D and capital investments over the next decade, enhancing its ability to deliver innovative medicines.
Feb 23, 2026 · 8 articles
Business
AbbVie Inc. made a US$10 million payment to Nxera Pharma, indicating progress in their collaboration to discover novel medicines for neurological diseases. This advancement could lead to new product development for AbbVie Inc.
Apr 20, 2026 · 9 articles
Regulatory
AbbVie, a multinational innovator, may benefit from increased patient numbers for its therapies in India due to the customs duty exemption on cancer drugs.
Feb 01, 2026 · 9 articles
Business
AbbVie had senior leaders participate in the BIOSeedin Winter Innovation Partnering Summit, contributing to discussions on global strategies and innovation in the biopharmaceutical industry.
Feb 02, 2026 · 7 articles
Tech
AbbVie has a collaboration and license option agreement with ADARx Pharmaceuticals to develop siRNA therapeutics. While not directly impacted by this specific event, the success of ADARx Pharmaceuticals' pipeline could indirectly benefit AbbVie.
Feb 20, 2026 · 7 articles
+ 1 more events
View on Dashboard
95
AbbVie made milestone payment Nxera PharmaNxera Pharma receives...
95
Nxera Pharma received milestone payment AbbVieNxera Pharma receives...
NEWSDESK
Track AbbVie live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard